Boston Scientific Corporation (BSX) saw its shares tumble approximately 10% in midday trading on Wednesday, reaching a session low of $50.60 and marking the stock's weakest level in over two years. The sharp decline followed remarks from CEO Michael Mahoney at the Bernstein Annual Strategic Decisions Conference, where he indicated that adoption of the company's key Watchman heart device is decelerating.
Watchman Growth Concerns
The Watchman implant, designed to prevent stroke in atrial fibrillation patients who cannot tolerate long-term blood thinners, has been a major growth driver for Boston Scientific. However, Mahoney revealed that stand-alone Watchman procedures have become less common in 2026, with physicians increasingly combining the implant with other cardiac treatments in a single procedure rather than performing it separately. He warned that Watchman sales are unlikely to grow in dollar terms from the first quarter into the second, and may also stall in the third quarter.
Recent Forecast Cuts Amplify Pressure
This development comes on the heels of a downward revision to Boston Scientific's 2026 organic revenue growth forecast just last month. The company now expects organic revenue growth of 6.5% to 8%, down sharply from its earlier projection of 10% to 11%. Organic revenue excludes the impact of acquisitions, divestitures, and currency fluctuations. Despite the headwinds, management has maintained its full-year organic revenue growth target of 6.5% to 8%.
Analyst Reactions and Price Target Cuts
Wall Street reacted swiftly to the update. Bernstein analyst Christian Moore noted that the outlook is "a bit below Street" expectations. J.P. Morgan's Robbie Marcus commented that the remarks "push off" clarity on whether negative revisions have ended. Stifel's Rick Wise lowered his price target on Boston Scientific to $75 from $85, though he maintained a buy rating, citing "near-term uncertainties." Bloomberg Intelligence's Matt Henriksson estimated that if Watchman sales continue to slow, total revenue could face a headwind of 0.8 to 1.3 percentage points. BofA slashed its price target to $68 from $105, while retaining a buy rating.
Competitive Pressures Mount
Beyond Watchman, Boston Scientific is grappling with intensifying competition in its electrophysiology unit, which produces tools for heart rhythm treatments. Mahoney acknowledged that rivals Medtronic, Johnson & Johnson, and Abbott are gaining market share with new product launches. The company is also facing pricing pressure in cardiac rhythm management and urology, exacerbated by commercial changes related to its Axonics acquisition and increased hiring needs.
Market Implications
The latest warning has reignited investor concerns about the visibility of growth across Boston Scientific's portfolio, particularly in Watchman, electrophysiology, and urology. With April's forecast cut already weighing on sentiment, the additional caution from management leaves the company with less margin for error. The stock's slide to a two-year low underscores the market's diminished confidence in a near-term recovery.
